BioStock: SynAct completes patient recruitment ahead of schedule

SynAct Pharma has completed the patient recruitment to the phase IIb trial EXPAND with resomelagon (AP1189) in newly diagnosed, severe rheumatoid arthritis. The last patient was enrolled well ahead of schedule, enabling reporting of top-line data in about five months. The company’s CSO Thomas Jonassen commented on the progress to BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/04/synact-completes-patient-recruitment-ahead-of-schedule/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se